Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 380

1.

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.

J Am Soc Nephrol. 2005 Jul;16(7):2205-15. Epub 2005 May 25.

2.

Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6.

3.

Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.

Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H.

Bone. 2009 Apr;44(4):678-83. doi: 10.1016/j.bone.2008.11.016. Epub 2008 Dec 9.

PMID:
19111635
4.

Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.

Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y.

Am J Transplant. 2007 May;7(5):1193-200. Epub 2007 Mar 12.

6.

Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.

Damasiewicz MJ, Toussaint ND, Polkinghorne KR.

Nephrology (Carlton). 2011 Mar;16(3):261-8. doi: 10.1111/j.1440-1797.2011.01443.x. Review.

PMID:
21265930
7.

Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.

Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y.

Ther Apher Dial. 2007 Oct;11 Suppl 1:S32-7. Review.

PMID:
17976083
8.

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.

Am J Kidney Dis. 2004 Sep;44(3):481-7.

PMID:
15332221
9.

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.

Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H.

Bone. 2009 Nov;45(5):949-55. doi: 10.1016/j.bone.2009.07.016. Epub 2009 Jul 23.

PMID:
19631779
10.

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.

Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M.

J Am Soc Nephrol. 2008 Mar;19(3):615-23. doi: 10.1681/ASN.2007060673. Epub 2008 Jan 23. Erratum in: J Am Soc Nephrol. 2009 Jan;20(1):229.

11.

[Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].

Goto S, Fukagawa M.

Clin Calcium. 2009 Jun;19(6):809-14. doi: CliCa0906809814. Review. Japanese.

PMID:
19483275
12.

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M.

Am J Kidney Dis. 2004 Aug;44(2):250-6.

PMID:
15264182
13.

Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.

Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, Stumpf UC.

Clin Lab. 2009;55(3-4):144-52.

PMID:
19462937
14.

Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.

Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK.

J Bone Miner Res. 2005 Nov;20(11):1944-50. Epub 2005 Jul 18.

15.

Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients?

Lomonte C, Antonelli M, Vernaglione L, Cazzato F, Casucci F, Chimienti D, Bruno A, Cocola S, Verrelli EA, Basile C.

J Nephrol. 2005 Jan-Feb;18(1):96-101.

PMID:
15772930
16.
17.

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?

Peiskerová M, Kalousová M, Kratochvílová M, Dusilová-Sulková S, Uhrová J, Bandúr S, Malbohan IM, Zima T, Tesar V.

Kidney Blood Press Res. 2009;32(4):276-83. doi: 10.1159/000243050. Epub 2009 Oct 1.

PMID:
19797911
18.

Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

Martin KJ, González EA.

Clin J Am Soc Nephrol. 2011 Feb;6(2):440-6. doi: 10.2215/CJN.05130610. Epub 2011 Feb 3. Review.

19.

Pathogenesis of secondary hyperparathyroidism.

Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D.

Int J Artif Organs. 2009 Feb;32(2):75-80. Review.

PMID:
19363778
20.

Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.

Gutiérrez OM.

Clin J Am Soc Nephrol. 2010 Sep;5(9):1710-6. doi: 10.2215/CJN.02640310. Epub 2010 May 27. Review.

Items per page

Supplemental Content

Write to the Help Desk